Q Therapeutics qthera.com


Public list: Pharma Startups (4740) Rare Diseases (230) Neuroscience Startups (942)

Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.

Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.

Company (Alive / Active)

Phone: 801-582-5400

Fax:

615 Arapeen Drive
Suite 102
Salt Lake City, 84108
Utah, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Q Therapeutics $9M Jun 18, 2010
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Q Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Tercica

Brisbane, California, United States
AcquiredTercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for pediatric and adult growth disorders, and for adult metabolic disorders. For further information on Tercica, please visit www.tercica.com.Login to see details

Rimon Therapeutics

Ontario, Canada
Alive / ActiveRimon Therapeutics, through the application of its polymer chemistry platform, is developing therapeutics to address unmet needs in important disease indicators with large markets. Rimon's therapeutic polymers - trademarked Theramers - are in that they deliver therapeutic effect without incorporating or releasing drugs. Theramers are intended to be used as solids-scaffolds, microbeeds and coatings - acting locally, without systemic consequences.Login to see details
See all 18 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Engineering mesenchymal stem cells using homologous recombination Nov 10, 2015 Application